- CRH Medical Corporation (“CRH”), a wholly owned subsidiary of WELL Health that provides physicians with innovative services and products for the treatment of gastrointestinal diseases, completes majority stake acquisition for 51% of Northern Georgia Anesthesia Associates, LLC. (“NGAA”) and 51% of Myrtle Beach Anesthesia Associates, LLC. (“MBAA”)
- The acquisition of NGAA creates a strategic partnership between CRH and 10 GI physicians in the Atlanta metro market while adding two additional sites of service
- The acquisition of MBAA creates a strategic partnership between CRH and 5 GI physicians in the Myrtle Beach market while adding one site of service
- The combined estimated annualized revenue run-rate is approximately US$6.5 million and will be immediately accretive to Cash Flow and EBITDA(1)
- These accretive acquisitions add increased scale to CRH’s already significant Georgia presence while also expanding within South Carolina since entering the market in mid-2024
ATLANTA, GA, June 2, 2025 – CRH Medical Corporation, a leading provider of products and services for gastrointestinal providers, is pleased to announce it has completed two accretive transactions; a 51% stake in Northern Georgia Anesthesia Associates, LLC (“NGAA”) and a 51% stake in Myrtle Beach Anesthesia Associates, LLC (“MBAA”), both of which are providers of gastrointestinal (GI) related anesthesia services.
Jay Kreger, CEO of CRH, commented, “We are very excited to partner with these two prominent GI groups to continue to provide high-quality anesthesia care to patients. Together with our new GI partners, CRH will continue to grow its footprint in the Atlanta and Myrtle Beach markets.”
NGAA performs GI anesthesia services at two endoscopic surgery locations in the Atlanta metro area while MBAA performs services at one endoscopy center in Myrtle Beach. The combined majority acquisitions are expected to be immediately accretive to CRH’s cashflows and represent an estimated current annual revenue run-rate of approximately US$6.5 million.
Footnotes:
- Earnings before interest, taxes, depreciation, and amortization (“EBITDA”) and EBITDA Margin are each non-GAAP measures. EBITDA should not be construed as alternatives to net income/loss determined in accordance with International Financial Reporting Standards (“IFRS”). EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. The Company believes that EBITDA is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements, service future interest and principal debt repayments and fund future growth initiatives.
About CRH Medical Corporation
CRH is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. CRH also provides locum tenens and permanent placement anesthesia staffing solutions to a network of customers which include provider groups, hospitals, and ASCs. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 50 anesthesia acquisitions, and now serves over 140 ambulatory surgery centers in 20 states. In addition, CRH owns the “CRH O’Regan System,” a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. The CRH O’Regan System is currently used in all 50 US states, Puerto Rico, USVI, and Canada. Learn more at https://crhmedcorp.com.
For more information:
Jay Kreger
Chief Executive Officer
CRH Medical Corporation
Phone: 404.592.9282
Email: jkreger@crhmedcorp.com